ArticleEuropean radiology2026
Human-AI collaboration using GPT-5 for MR grading of endolymphatic hydrops in Ménière's disease.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate GPT-5 for grading cochlear and vestibular endolymphatic hydrops (EH) on delayed gadolinium-enhanced 3D-FLAIR MRI in Ménière's disease (MD) and to assess prompting strategies and human-AI collaboration. MATERIALS AND
methodsThis retrospective study included 436 patients with MD (872 ears). GPT-5 graded cochlear and vestibular EH under multiple prompting strategies and was compared with junior and senior neuroradiologists in independent and GPT-5-assisted workflows. Accuracy (ACC), AUC, F1 score, agreement, and expert-rated clinical usefulness were assessed.
resultsUnder basic prompting strategies without structured image descriptions, diagnostic performance remained poor: cochlear hydrops grading ACC reached only 25%, and vestibular hydrops grading ACC reached only 39%, despite the inclusion of clinical history or few-shot examples. In contrast, with enhanced prompting that integrated structured image descriptions, clinical context, and representative examples, GPT-5 showed substantially improved performance, achieving accuracies of 87% for cochlear grading and 80% for vestibular grading, with improved agreement and favorable expert ratings. In human-AI interaction experiments, the Human-first mode improved junior physicians' performance, increasing cochlear grading ACC from 36% to 59% and vestibular grading ACC from 42% to 53%.
conclusionGPT-5 demonstrated limited capability to independently grade EH on MRI when relying primarily on image input. Acceptable diagnostic performance was achieved only after incorporating structured image descriptions, clinical context and representative examples. Under these enhanced prompting conditions, GPT-5 showed potential as an assistive tool for human-AI collaborative interpretation, particularly for less experienced physicians, rather than as a fully autonomous diagnostic system. KEY POINTS: Question Accurate grading of endolymphatic hydrops on 3D-FLAIR MRI is critical for managing Ménière's disease, but current interpretation lacks standardization and efficiency. Findings GPT-5 showed poor EH MRI grading accuracy without image descriptions, while optimized prompting and human-AI collaboration markedly improved performance toward expert interpretation. Clinical relevance Acceptable MRI grading of endolymphatic hydrops by GPT-5 requires structured image descriptions and contextual prompting. This supports its role as a human-AI collaborative assistive tool, not an autonomous system, potentially reducing reliance on limited medical resources.
Indexed as
Identifiers
42706360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.